Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Price and Innovation:The Growth of Private Label in 2010
OTC National, May 2010
© Euromonitor International
2
Industry: Consumer Health
AGENDA
Consumer Health Performance
Why Private Label?
Consumers
Retailers
Future of Private Label
© Euromonitor International
3
Industry: Consumer Health
Consumer Health in 2009: A Steady Performer
Global Performance
• Preventative health measures against chronic diseases and concerns about the H1N1 virus
drove spending for OTC treatments and vitamins and dietary supplements.
• Consumers increased their use of herbal/traditional remedies to save money, to stay healthy
following a natural approach, and to cope with stress.
• Consumers and healthcare systems sought ways to reduce their cost burdens: price controls,
generics/private label or RX to OTC switches.
0
1
2
3
4
5
6
120,000
125,000
130,000
135,000
140,000
145,000
150,000
155,000
160,000
165,000
170,000
2004 2005 2006 2007 2008 2009
Consumer Health – Global Sales 2004-2009
Retail Value RSP - US$ mn - Fixed 2009 Exchange Rates Growth Rate %
© Euromonitor International
4
Industry: Consumer Health
OTC Healthcare Categories
Global Performance
0
2
4
6
8
2004-05 2005-06 2006-07 2007-08 2008-09
Ye
ar-
on
-Ye
ar
Gro
wth
(%
)
Fixed Exchange Rates 2009
Top Five OTC Categories – Retail Value RSP – US$ mn 2004-2009
Analgesics Cough, Cold and Allergy (Hay Fever) Remedies
Digestive Remedies Eye Care
Medicated Skin Care
© Euromonitor International
5
Industry: Consumer Health
OTC Healthcare Categories
Global Performance
-5
0
5
10
15
20
25
30
35
2004-5 2005-6 2006-7 2007-8 2008-9
Top Five OTC Categories: Private Label Growth 2004-09, Retail Value RSP in US$ mn
Analgesics Cough, Cold and Allergy (Hay Fever Remedies)
Digestive Remedies Eye Care
Medicated Skin Care
© Euromonitor International
6
Industry: Consumer Health
Global market share for private label products increased from 5.3% in 2008 to 5.6% in 2009
Perrigo and Teva are pursuing aggressive acquisition
strategies in Latin America and Asia
Pacific
Consumers coping with a shrinking
wallet like paying lower prices for
“commodity” healthcare products
Retailers enjoy a higher profit margin from private label products and are
devoting more shelf space to them
Private Label Performance
Global Performance
© Euromonitor International
7
Industry: Consumer Health
• Private label saw the most growth in “safe” and less regulated categories.
• Low-priced branded options in mature categories represent a competitive challenge.
• Acceptance of private label and generic products depends on consumer perceptions.
• The emerging market of OTC private label/generics is supported by recommendations by
doctors, health practitioners and pharmacists.
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
2001 2002 2003 2004 2005 2006 2007 2008 2009
Reta
il V
alu
e R
SP
–U
S$
mn
–F
ixe
d E
xch
an
ge
Ra
tes
Private Label – Global Sales 2001-2009
Private Label Performance
Global Performance
© Euromonitor International
8
Industry: Consumer Health
Private Label Global Growth
Global Performance
© Euromonitor International
9
Industry: Consumer Health
AGENDA
Consumer Health Performance
Why Private Label?
Consumers
Retailers
Future of Private Label
© Euromonitor International
10
Industry: Consumer Health
• Multiple, contradictory concerns shaped consumer purchasing decisions:
• For critical healthcare concerns, like H1N1, consumers still turned to the OTC
industry because of general trust in the safety and quality of the products.
• Consumers also needed to remain healthy to be able to work. When they were
sick or injured, they used products that provided immediate relief.
• For products used often, consumers turned to private label to ease the burden on
their shrinking wallets.
Consumers Point of View
Why Private Label?
Consumer expenditure
comes under pressure
Consumers need to stay healthy to work or cannot afford to be ill
Private label is a major beneficiary of a shrinking
consumer wallet
© Euromonitor International
11
Industry: Consumer Health
Consumers POV: Price
Why Private Label?
© Euromonitor International
12
Industry: Consumer Health
Product Brand Unit Price Private Label Unit
Price
Retailer
Ibuprofen 200 mg. $0.05 (Advil) $0.01 (Kirkland
Signature)
Costco
Proton Pump
Inhibitor
$0.75 (Prilosec
OTC)
$0.60 (Target
omeprazole)
Target
Cough Remedy $57.71 (Vicks
Formula 44-D)
$55.12 (Wal-
Tussin)
Drugstore.com,
Walgreen’s
Topical Allergy
Remedy
$44.03 (Caladryl) $29.34 (Walgreen’s
Calahist)
Walgreen’s
Liquid Bandages $236.36 (Skin
Shields)
$168.73
(Walgreen’s Liquid
Bandages)
Walgreen’s
Consumers POV: Price
Why Private Label?
Unit Price Comparison of Popular OTC Products
Note: Prices were obtained during Euromonitor Fall 2009 Storecheck. Pack sizes and units are the same for each pair of
products.
© Euromonitor International
13
Industry: Consumer Health
• Consumers and medical professionals
no longer perceive private label/store
brand/generic products as being
inferior in quality or innovation.
• Caveat: consumers in developing
countries trust multinational or
international brands more than local
private label products.
• Generics manufacturers are arguably
more innovative – as a strategy to
convince retailers to add private
label products.
• New product innovation in the form
of customisation, dosing devices and
flavours can easily be done by both
branded and generic manufacturers.
Consumers POV: Quality and Innovation
Why Private Label?
© Euromonitor International
14
Industry: Consumer Health
AGENDA
Consumer Health Performance
Why Private Label?
Consumers
Retailers
Future of Private Label
© Euromonitor International
15
Industry: Consumer Health
• Channel Redistribution
•SKU Reduction
•Importance of the Grocery Channel
•Expansion of Western/Developed Country-Style Retailing
Retail Distribution Changes
Why Private Label?
© Euromonitor International
16
Industry: Consumer Health
• Project Impact set out to change
“the shopping experience in the
stores”, including stripping out
brands that were not generating
volume sell-through.
• Walmart has created more room
for its private label products.
• During the economic downturn Wal-
Mart itself has been concentrating
on the efficiency gains brought by
Project Impact and on rejuvenating
its Great Value range.
• The moves together have enabled
Walmart to hold less stock, which
among other things has helped to
boost margins.
Why Private Label?
SKU Reduction: Walmart’s Project Impact
Note: Graphs are taken from Walmart
presentations as part of its 16th Annual Meeting for
the Investment Community (21st October 2009)
© Euromonitor International
17
Industry: Consumer Health
Channel Redistribution for Consumer Health
Why Private Label?
0
20
40
60
80
100
2004 2005 2006 2007 2008 2009
Re
tail
Va
lue
RS
P -
% b
rea
kd
ow
n
Evolution of Distribution Channels 2004-09
Internet Retailing
Other Non-Grocery Retailers
Mass Merchandisers
Healthfood shops
Parapharmacies/Drugstores
Chemists/Pharmacies
Grocery Retailers
© Euromonitor International
18
Industry: Consumer Health
• Private label requires modern
grocery channels to exist in a
country.
• As modern grocery channels
have expanded out from
Western markets, they have
taken their private label ranges
with them.
• Faced with the arrival of foreign
competitors and spurred on by
the positive effects that private
label can bring, retailers
operating in emerging
markets within modern grocery
channels have adopted similar
strategies.
Why Private Label?
Importance of the Grocery Channel
© Euromonitor International
19
Industry: Consumer Health
• The expansion of modern
grocery channels across all
markets is set to continue in the
forecast period.
• The modernisation of grocery
retailing brings chains into
consumers’ lives and buying
decisions.
• The development of private label
will not be solely due to Western
retailers importing successful
strategies from their home markets.
• The rise of modern grocery
channels across all markets will
likely cause problems for brand
manufacturers world-wide.
• As the pace of modernisation
quickens, private label is likely to
be adopted earlier and across a
greater range of product areas.
Why Private label?
Expansion of the Grocery Channel
© Euromonitor International
20
Industry: Consumer Health
• The arrival and expansion of
Western retailers in emerging
markets will help develop private label
in these countries.
• Western retailers have grown their
share of value sales across the
regions.
• Consumers are moving towards
private label products due to
education about benefits and lower
prices.
• Retailers still have to overcome
consumers’ negative perception of
private label in some countries.
• While brands are central to consumers’
buying decisions at the moment, with
effective advertising and marketing in
the future it could be private label.
Why Private label?
Expansion of Western-Style Retailing
© Euromonitor International
21
Industry: Consumer Health
AGENDA
Consumer Health Performance
Why Private Label?
Consumers
Retailers
Future of Private Label
© Euromonitor International
22
Industry: Consumer Health
The longer that consumers are “forced” to buy private label by economic factors,
the more likely that such patterns will become engrained.
Future of Private Label
Macroeconomics Should Support Growth in the Short Term
© Euromonitor International
23
Industry: Consumer Health
Private Label:
The Positives
Private Label:
The Challenges
The Private Label Balancing Act
Future of Private Label
Consumer perception of private
label is rising as they are forced or
are encouraged to purchase them
© Euromonitor International
24
Industry: Consumer Health
Strengths
• Commoditisation of products
• Successful ranges become very popular
Weaknesses
• Consumer perception differs markedly globally
• Growth requires modern grocery retailing
Opportunities
• Low global penetration
• Product areas determines success
Threats
• Retailers take private label penetration too far
• Internet retailing limits growth opportunities
Private Label SWOT
Future of Private Label
© Euromonitor International
25
Industry: Consumer Health
Learn More
To find out more about Euromonitor International's complete range of business intelligence on industries, countries and consumers please visit www.euromonitor.com or contact your local Euromonitor International office:
Disclaimer
Much of the information in this briefing is of a statistical nature and, while every attempt has been made to ensure accuracy and reliability, Euromonitor International cannot be held responsible for omissions or errors
Figures in tables and analyses are calculated from unrounded data and may not sum. Analyses found in the briefings may not totally reflect the companies’ opinions, reader discretion is advised
London + 44 (0)20 7251 8024Chicago +1 312 922 1115Singapore +65 6429 0590Shanghai +86 21 63726288
Vilnius +370 5 243 1577Dubai +971 4 372 4363Cape Town +27 21 552 0037Santiago +56 2 4332226
Thank you.
Q&A
Samantha Chmelik, Head of Global Consumer Health
Research, Euromonitor International